NEW CASTLE, Del., Aug. 14, 2025 /PRNewswire/ — IgniteData, a leader in intelligent clinical trial data automation, today announced the close of its Series A funding round, led by FCA Venture Partners, with strong participation from existing investors including SpringTide, which led the company’s previous funding round, and Oncology Ventures. The investment will accelerate IgniteData’s growth as it scales its global research site network and advances its flagship product, IgniteData Archer — a platform that enables seamless transfer of clinical trial data from electronic health records (EHR) to electronic data capture (EDC) systems and data warehouses.

The financing reflects growing industry validation of IgniteData’s platform, which enables real-time, automated transfer of complex clinical data between healthcare providers and pharmaceutical sponsors. IgniteData is already deployed at several of the world’s most prestigious cancer centers and is rapidly expanding into community hospitals and health systems across North America, Europe, and Asia.

“This round is about scale,” said Zach Taft, CEO of IgniteData. “The demand for smarter, faster clinical trials is exploding. We’ve already validated product-market fit and built deep integrations with top-tier sponsors and sites. This investment enables us to extend our footprint, unlock new data domains, and deliver on the industry’s need for intelligent data solutions at a global scale.”

The round was led by FCA Venture Partners, a Nashville-based firm with deep experience in healthcare innovation. FCA’s backing brings not only capital but strategic connections to influential integrated delivery networks (IDNs) and hospital systems.

“IgniteData represents a compelling opportunity to invest in a company that has established itself as the leader in this fast-evolving space,” said Matt King, Managing Partner at FCA Venture Partners. “Their adoption by the world’s top cancer centers and leading pharmaceutical sponsors demonstrates the value of their solution. IgniteData has developed a scalable data automation platform that delivers measurable results. We look forward to supporting their continued growth, global expansion, and the continued advancement of their transformative technology.”

This Series A follows an earlier investment that enabled the company to demonstrate market fit and commercial momentum. Returning investors SpringTide and Oncology Ventures increased their positions in this round, underscoring confidence in IgniteData’s trajectory.

“We backed IgniteData early because we believed in their vision to revolutionize clinical trials through intelligent automation — and to truly reduce burden on clinical sites while accelerating research,” said Ryan Morley, Partner at SpringTide “Today, we’re doubling down because they’ve exceeded expectations. They’re not just leading — they’re winning, and they’re transforming how sites and sponsors work together.”

The company’s roadmap includes further expansion of its site network, international deployments, and new product modules designed to unlock previously inaccessible clinical data. IgniteData has already begun leveraging large language models and intelligent data mapping to improve trial speed, data quality, and site-sponsor collaboration.

This announcement precedes several upcoming milestones, including board expansion, strategic partnerships, and product innovation that will continue to position IgniteData at the forefront of modernizing clinical trials.

About IgniteData
IgniteData is on a mission to revolutionize clinical trials through intelligent automation. By enabling real-time, secure transfer of clinical data between healthcare providers and life science companies, IgniteData accelerates research while reducing burden on clinical sites. With deployments across premier research centers and partnerships with top pharmaceutical sponsors, IgniteData is redefining what’s possible in clinical trial operations.

SOURCE IgniteData

Copyright © 2025 Cision US Inc.